329 related articles for article (PubMed ID: 33997867)
1. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
3. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
5. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.
Phung CD; Nguyen HT; Choi JY; Pham TT; Acharya S; Timilshina M; Chang JH; Kim JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
J Control Release; 2019 Dec; 315():126-138. PubMed ID: 31672625
[TBL] [Abstract][Full Text] [Related]
6. Stimuli-responsive nanoparticles for the codelivery of chemotherapeutic agents doxorubicin and siPD-L1 to enhance the antitumor effect.
Zhou YJ; Wan WJ; Tong Y; Chen MT; Wang DD; Wang Y; You BG; Liu Y; Zhang XN
J Biomed Mater Res B Appl Biomater; 2020 May; 108(4):1710-1724. PubMed ID: 31746127
[TBL] [Abstract][Full Text] [Related]
7. Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
Cai S; Chen Z; Wang Y; Wang M; Wu J; Tong Y; Chen L; Lu C; Yang H
Theranostics; 2021; 11(4):1970-1981. PubMed ID: 33408792
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy.
Liu J; Zhao Z; Qiu N; Zhou Q; Wang G; Jiang H; Piao Y; Zhou Z; Tang J; Shen Y
Nat Commun; 2021 Apr; 12(1):2425. PubMed ID: 33893275
[TBL] [Abstract][Full Text] [Related]
9. Dissolving microneedles-based programmed delivery system for enhanced chemo-immunotherapy of melanoma.
Tian Y; Jing H; Wang Q; Hu S; Wu Z; Duan Y
J Control Release; 2023 Aug; 360():630-646. PubMed ID: 37414221
[TBL] [Abstract][Full Text] [Related]
10. Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy.
Xie F; Tang S; Zhang Y; Zhao Y; Lin Y; Yao Y; Wang M; Gu Z; Wan J
ACS Nano; 2024 Jan; 18(2):1690-1701. PubMed ID: 38165832
[TBL] [Abstract][Full Text] [Related]
11. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
[TBL] [Abstract][Full Text] [Related]
12. Design of an Injectable Polypeptide Hydrogel Depot Containing the Immune Checkpoint Blocker Anti-PD-L1 and Doxorubicin to Enhance Antitumor Combination Therapy.
Shi Y; Li D; He C; Chen X
Macromol Biosci; 2021 Jun; 21(6):e2100049. PubMed ID: 33871152
[TBL] [Abstract][Full Text] [Related]
13. Sequentially pH-Responsive Drug-Delivery Nanosystem for Tumor Immunogenic Cell Death and Cooperating with Immune Checkpoint Blockade for Efficient Cancer Chemoimmunotherapy.
Jiang M; Chen W; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
ACS Appl Mater Interfaces; 2021 Sep; 13(37):43963-43974. PubMed ID: 34506118
[TBL] [Abstract][Full Text] [Related]
14. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
[TBL] [Abstract][Full Text] [Related]
15. pH-Sensitive self-assembling nanoparticles for tumor near-infrared fluorescence imaging and chemo-photodynamic combination therapy.
Hou W; Zhao X; Qian X; Pan F; Zhang C; Yang Y; de la Fuente JM; Cui D
Nanoscale; 2016 Jan; 8(1):104-16. PubMed ID: 26607263
[TBL] [Abstract][Full Text] [Related]
16. DNA nanodevice as a multi-module co-delivery platform for combination cancer immunotherapy.
Nie C; Ye J; Jiang JH; Chu X
J Colloid Interface Sci; 2024 Aug; 667():1-11. PubMed ID: 38615618
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J
Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580
[TBL] [Abstract][Full Text] [Related]
18. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
19. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
[TBL] [Abstract][Full Text] [Related]
20. A pH-responsive Pickering Nanoemulsion for specified spatial delivery of Immune Checkpoint Inhibitor and Chemotherapy agent to Tumors.
Jia L; Pang M; Fan M; Tan X; Wang Y; Huang M; Liu Y; Wang Q; Zhu Y; Yang X
Theranostics; 2020; 10(22):9956-9969. PubMed ID: 32929327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
